Competition Council Advocates Careful Drug Pricing Reform in Morocco
The Competition Council of Morocco has issued a significant advisory urging the government to adopt a careful and methodical approach regarding a draft decree aimed at reforming the pricing structure of pharmaceutical products. This advisory, reported by the L’Economiste daily, emphasizes the necessity of establishing strong legal foundations and conducting a thorough prior assessment of the economic implications of such a reform. The government's dual objectives are to enhance access to essential treatments while ensuring the financial sustainability of the compulsory health insurance system.
The proposed decree outlines a progressive pricing mechanism for generic drugs, taking into account their order of market entry, the price range of reference products, and their manufacturing origins. Notably, the draft aims to eliminate the historically applied 10% markup on imported medications and permits negotiated rebates on treatments that impose significant financial burdens on the health system.
In light of these developments, the Competition Council has recommended that a comprehensive impact analysis be undertaken before any implementation occurs. This analysis should evaluate the current pricing system and identify potential risks across the pharmaceutical sector. Furthermore, the Council has raised concerns regarding the continuity of supply for essential medicines. The draft decree includes exceptional measures intended to ensure the availability of these medicines, and the Council insists that the conditions triggering these measures must be clearly defined and linked to the existing Code of Medicines and Pharmacy, thereby preventing redundancy or legal ambiguities.
According to L’Economiste, the success of these reforms hinges on strengthening the Moroccan Agency for Medicines and Health Products. This agency will require adequate human, technical, and analytical resources to effectively monitor stock levels and ensure prompt responses to market changes. The Council also warns against introducing numerous amendments to the original text of the reform, as this could lead to vulnerabilities. Instead, it advocates for a new, consolidated decree with consistent versions in both Arabic and French, while relegating negotiation and rebate processes to separate regulatory frameworks.
Ultimately, the Council emphasizes that the success of this overhaul will depend on a well-managed transition strategy. It calls for a detailed and balanced implementation timeline that encompasses all medications, coupled with a monitoring and review mechanism. Close collaboration with pharmaceutical manufacturers and pharmacists is deemed essential to strike a balance between controlling health expenditures and maintaining economic equilibrium within the market.
As reported by northafricapost.com.
